Business Wire

CA-HYPERICE

15.9.2022 12:02:01 CEST | Business Wire | Press release

Share
Hyperice Brings the Heat With Introduction of All-New Venom Go and Venom 2

Hyperice, a global high-performance wellness brand, today announced two new products within their heat therapy category, Venom Go and Venom 2, alongside HyperHeat™ technology for the fastest, most consistent and even distribution of heat to relieve sore, stiff muscles and promote wellness. Venom Go advances the capabilities of the Venom line further with the ability to deliver heat and vibration spot treatment in more areas, such as the neck, shoulder, upper and lower back, calf and forearm. Designed with flexibility in mind, Venom Go can be utilized in more environments than ever before, with unmatched versatility and customizations, delivering instant muscle relief wherever the body needs it most. Venom 2 is the most advanced heat and massage wrap on the market and carries on the legacy built by the original Venom line, which revolutionized the traditional heating pad for consumers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005442/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

"The new Venom Go allows me to be even more targeted with muscle recovery to keep me moving at my best so I can help others move at their best too.” -Robin Arzón, Hyperice Athlete-Investor, and Peloton Vice President of Fitness Programming. (Photo: Business Wire)

“The new Venom Go is a revolutionary product for us as it widens the application of our Venom technology and addresses the need for a powerful heat and vibration solution for spot treatment,” said Jim Huether, CEO of Hyperice. “It’s been six years since the debut of heat and vibration technology from Hyperice, we’ve now significantly enhanced the Venom user experience and added our patented HyperHeat™ technology, all while staying true to the core elements of the original product that made people fall in love with it. The Venom line is one of our fastest growing product lines, and we expect this trend to continue in the U.S. and throughout the world.”

INTRODUCING VENOM GO

The Venom Go is a heat and vibration wearable that consists of a control pod that magnetically connects to an adhesive pad and is applied directly to the skin. Venom Go pads are reusable approximately 20 to 40 times each (depending on placement on body and any sweat, lotion or oil that may be on the skin) and cover 13.5 square inches, allowing users to receive direct treatment to more areas of the body than ever before. Users can select from 3 levels of heat and 3 levels of vibration via easy to use button control on the pod. Sore and stiff muscles can now receive instant treatment, with Venom Go reaching up to 113℉ (45°C) in 90 seconds after applied to the skin - or just 20 seconds prior to being applied to the skin.

The Venom Go control pod and pad weighs a mere 0.2 lbs, and holds a battery life of up to 60 minutes on a full charge, with a standard session running for 10 minutes. The Venom Go is charged via USB connection and is TSA approved for convenient use while traveling. Utilizing Bluetooth connectivity, the Venom Go is controlled via the Hyperice App, with users having the ability to sync multiple pods to deliver tailored spot treatments across different areas of the body at once for a unique heat and vibration therapy experience.

“Recovery plays a key role in performing your best every day,” said Robin Arzón, Hyperice Athlete-Investor, and Peloton Vice President of Fitness Programming. “Venom has always been a staple product in my warmup and recovery routines. Vibration and heat are both critical components in the equation. The new Venom Go allows me to be even more targeted with muscle recovery to keep me moving at my best so I can help others move at their best too.”

The introduction of the Venom Go comes on the heels of the introduction of the Normatec Go (currently only available in the US), and now provides a holistic suite of products within Hyperice’s Go series (Hypersphere Mini, Hypervolt Go 2, Vyper Go, Normatec Go). Portable and mobile adaptations of each product line offer users maximum flexibility to experience the benefits of warm up and recovery technology in more places, and at more price points, than ever before.

“With the Venom Go, users will be able to experience the same benefits they have grown to know and love in the Venom line, but in many more targeted areas for relief,” added Huether. “This product is amazing for anyone with soreness, stiffness or pain in targeted areas, and furthers our mission to help as many people as possible improve their daily lives through recovery and movement.”

INTRODUCING VENOM 2

The Venom 2, which comes in versions for the back, leg and shoulder (left or right), has more-than-doubled its treatment area, increasing the overall heating surface by 111% (94 square inches), and is encased in a new silicone surface for easier cleaning. Venom 2 delivers up to a three-hour battery life on a full charge, and heats to 131℉ (55°C) in just one minute, which is four times faster than the original Venom, and six times faster than a traditional heating pad. Users will also experience a lighter version of the Venom, as the weight drops by more than 23% from the original version, now weighing just two lbs.

“Heat therapy is such a critical component of my routine, from preparing for a game and getting my shoulder loose, to treating sore muscles in my arm between practices,” said Patrick Mahomes, Hyperice Athlete-Investor and Super Bowl Champion. “From pregame, to the training facility and home, the Venom line allows me to optimize my performance. The new Venom 2 improves the experience and I know will be a popular tool in the locker room.”

“As a footballer, I need to ensure that my body is ready to endure the rigors that come with a 90-minute match,” said Erling Haaland, Hyperice Athlete-Investor and global footballer. “Heat therapy is very important in ensuring my body is properly prepared and ready to go ahead of training or kickoff, and equally important in the time between match-days. I’m always looking for ways to give myself a competitive edge, and with Venom 2’s heating time, I feel the benefits quicker than ever before, and can be ready to take the pitch faster with my body ready to go.”

Through Bluetooth® connectivity, the Venom 2 is controlled via the Hyperice App, unlocking more routines to maximize and customize time, heat and vibration while using the device.

HYPERHEAT TECHNOLOGY

With the launch of Venom Go and the Venom 2, Hyperice also introduces their new HyperHeat™ technology which delivers a faster, more consistent distribution of heat across a greater surface area, allowing for a more premium experience for users.

“In 2015 we were getting requests from NBA players for a product that could heat the body pregame and keep the body warm when they came out of the game. Our answer was the Venom, the first heat and vibration wearable device, released in 2017,” said Anthony Katz, Hyperice Founder. “Over the past five years, the user base for the Venom has expanded far beyond performance athletes to everyday people who use the Venom to manage pain and soreness. The Venom 2 is a complete redesign and upgrade from the original model- every aspect of the product and experience have been improved.“

The Venom Go ($149; £159; €175) and Venom 2 line ($249; £269; €299) are available in North America as well as globally across all countries and regions where Hyperice is sold. For more information, please visit hyperice.com country-specific sites.

About Hyperice

Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), mind technology (Core by Hyperice) and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance and workplace wellness on a global scale. Hyperice’s transformative acquisitions of Normatec, RecoverX and Core have helped to accelerate its innovation agenda as it enters its next stage of global growth. For more information, visit the newly redesigned hyperice.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005442/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release

IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million

IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p

HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha

Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release

Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char

DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release

Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye